Indivior PLC

Отворен

1,242

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

1242

Максимум

1242

Ключови измерители

By Trading Economics

Приходи

-19M

47M

Продажби

-33M

266M

P/E

Средно за сектора

330

38.156

Марж на печалбата

17.669

Служители

1,030

EBITDA

-30M

76M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+10.23% upside

Пазарни показатели

By TradingEconomics

Пазарна капитализация

721M

1.5B

Предишно отваряне

1242

Предишно затваряне

1242

Indivior PLC Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

31.07.2025 г., 23:56 ч. UTC

Горещи акции

Stocks to Watch: Amazon, Bio-Rad, Coinbase, Mercer

31.07.2025 г., 23:48 ч. UTC

Пазарно говорене

Scentre Can Beat Annual Earnings Guidance -- Market Talk

31.07.2025 г., 23:45 ч. UTC

Пазарно говорене

Nikkei May Decline Amid Caution Over Earnings, Domestic Politics -- Market Talk

31.07.2025 г., 23:37 ч. UTC

Пазарно говорене

Market Talk Roundup: Latest on U.S. Politics

31.07.2025 г., 23:37 ч. UTC

Пазарно говорене

Gold Steady as Traders Eye Tariff-Deal Developments -- Market Talk

31.07.2025 г., 23:12 ч. UTC

Печалби

OCBC: Evolving Trade, Monetary Policies, Persistent Geopolitical Tensions Expected to Weigh on Growth Prospects >O39.SG

31.07.2025 г., 23:10 ч. UTC

Печалби

Oversea-Chinese Banking: Declining Interest-Rate Environment Weighed in Net Interest Income >O39.SG

31.07.2025 г., 23:09 ч. UTC

Печалби

Oversea-Chinese Banking 2Q Net Interest Income S$2.28B Vs. S$2.43B >O39.SG

31.07.2025 г., 23:08 ч. UTC

Печалби

Oversea-Chinese Banking 2Q Total Income S$3.55B Vs. S$3.63B >O39.SG

31.07.2025 г., 23:08 ч. UTC

Печалби

Oversea-Chinese Banking 2Q Net S$1.82B Vs. Net S$1.94B >O39.SG

31.07.2025 г., 23:01 ч. UTC

Печалби

Amazon Posts Higher Sales, Profit -- 3rd Update

31.07.2025 г., 22:08 ч. UTC

Пазарно говорене
Печалби

Amazon CEO Impressed by Deals Signed for Project Kuiper -- Market Talk

31.07.2025 г., 22:02 ч. UTC

Пазарно говорене
Печалби

Apple's FY Outlook Shows Sales Growth Won't Last -- Market Talk

31.07.2025 г., 21:57 ч. UTC

Пазарно говорене
Печалби

Amazon CEO Sees Strong Early Demand for Alexa+ -- Market Talk

31.07.2025 г., 21:50 ч. UTC

Печалби

Amazon Earnings Beat Expectations. Why the Stock Is Falling. -- Barrons.com

31.07.2025 г., 21:43 ч. UTC

Печалби

Apple's iPhone Sales Blow Past Estimates as Customers Raced to Beat Tariffs -- 2nd Update

31.07.2025 г., 21:29 ч. UTC

Печалби

Amazon to Invest More in Chips, Data Centers Amid Generative AI Opportunity, CFO Says

31.07.2025 г., 21:26 ч. UTC

Печалби

Apple Expects Revenue to Grow in Mid- to High-Single Digits in Current Quarter, CFO Says

31.07.2025 г., 21:26 ч. UTC

Печалби

MicroStrategy Beats Earnings Estimates. The Stock Rises. -- Barrons.com

31.07.2025 г., 21:22 ч. UTC

Печалби

Amazon Has Impressive Amount of Agreements for Project Kuiper, CEO Says

31.07.2025 г., 21:19 ч. UTC

Печалби

Apple Estimates Tariff Impact to Add $1.1B to Costs in Current Quarter, CEO Says

31.07.2025 г., 21:19 ч. UTC

Печалби

Apple Incurred $800M in Tariff-Related Costs in 2Q, CEO Says

31.07.2025 г., 21:14 ч. UTC

Печалби

Amazon's AWS is Seeing More Demand Than Supply, CEO Says

31.07.2025 г., 21:12 ч. UTC

Печалби

Amazon Saw Record Prime Sign-Ups in 3 Weeks Before Prime Day, CEO Says

31.07.2025 г., 21:10 ч. UTC

Печалби

Amazon Just Getting Started on Automation, Robotics to Boost Efficiency, CEO Says

31.07.2025 г., 21:09 ч. UTC

Печалби

Amazon Delivered to Prime Members at Record Pace in 2Q, CEO Says

31.07.2025 г., 21:09 ч. UTC

Печалби

Amazon CEO Sees Diversity of Sellers as Advantage for Inflation-Weary Consumers

31.07.2025 г., 21:08 ч. UTC

Печалби

Apple iPhone Revenue Performance Driven by Popularity of iPhone 16 Family, CEO Says

31.07.2025 г., 21:08 ч. UTC

Печалби

Amazon CEO Sees Strong Customer Adoption of Perishables Same-Day Delivery Pilot

31.07.2025 г., 21:05 ч. UTC

Печалби

Apple's iPhone Sales Blow Past Estimates as Customers Raced to Beat Tariffs -- Update

Indivior PLC Прогноза

Ценова цел

By TipRanks

10.23% нагоре

12-месечна прогноза

Среден 1,364.65 GBX  10.23%

Висок 1,637.581 GBX

Нисък 967.662 GBX

Според 4 анализатори от Wall Street, предложили 12-месечна ценова цел за Indivior PLC през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

4 ratings

4

Купи

0

Задържане

0

Продай

Финанси

$

Относно Indivior PLC

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.
help-icon Live chat